REPL News and Press, Replimune Group Inc.

2024-06-13 09:47:15 ET More on Replimune Group Replimune: Continuing To Justify The Bear Thesis (For Now) Replimune up 30% on results for RP1 combo in melanoma Seeking Alpha’s Quant Rating on Replimune Group Historical earnings data for Replimune Group...

- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Gold...

2024-06-07 07:00:05 ET Robert Burns from H.C. Wainwright issued a price target of $17.00 for REPL on 2024-06-07 06:07:00. The adjusted price target was set to $17.00. At the time of the announcement, REPL was trading at $7.11. The overall price target consensus is at $26...

2024-06-06 12:05:40 ET More on Replimune Group Replimune: Continuing To Justify The Bear Thesis (For Now) Seeking Alpha’s Quant Rating on Replimune Group Historical earnings data for Replimune Group Financial information for Replimune Group R...

Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 ...

2024-06-04 14:00:07 ET Peter Lawson from Barclays issued a price target of $13.00 for REPL on 2024-06-04 09:51:00. The adjusted price target was set to $13.00. At the time of the announcement, REPL was trading at $5.37. The overall price target consensus is at $30.33 wit...

-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data from IGNYTE trial -- -- RP2 as monother...

2024-06-02 15:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...